NTHI (NeOnc Technologies Holdings) ROA %: -1,146.57% (As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings ROA %?

NeOnc Technologies Holdings NTHI -0.90% 7 ROA % is -1,146.57% as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 99.08% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. NeOnc Technologies Holdings's annualized Net Income for the quarter that ended in Mar. 2026 was $-35.28 Mil. NeOnc Technologies Holdings's average Total Assets over the quarter that ended in Mar. 2026 was $3.08 Mil. Therefore, NeOnc Technologies Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was -1,146.57%.

The historical rank and industry rank for NeOnc Technologies Holdings's ROA % or its related term are showing as below:

NTHI' s ROA % Range Over the Past 10 Years
Min: -10550   Med: -1496.59   Max: -508.24
Current: -891.68

During the past 5 years, NeOnc Technologies Holdings's highest ROA % was -508.24%. The lowest was -10550.00%. And the median was -1496.59%.

NTHI's ROA % is ranked worse than
99.08% of 1417 companies
in the Biotechnology industry
Industry Median: -32.84 vs NTHI: -891.68

NeOnc Technologies Holdings  (NAS:NTHI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-35.28/3.077
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-35.28 / 0)*(0 / 3.077)
=Net Margin %*Asset Turnover
=N/A %*0
=-1,146.57 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


NeOnc Technologies Holdings ROA % Related Terms


NeOnc Technologies Holdings ROA % Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings ROA % Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
-10,550.00 -800.79 -1,496.59 -508.24 -1,991.54

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,180.69 -397.55 -974.80 -1,798.06 -1,146.57

NTHI vs GUTS, PEPG, ENGN: ROA % Comparison

For the Biotechnology subindustry, NeOnc Technologies Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeOnc Technologies Holdings ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where NeOnc Technologies Holdings's ROA % falls into.


NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings ROA % Calculation

NeOnc Technologies Holdings's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-62.146/( (3.417+2.824)/ 2 )
=-62.146/3.1205
=-1,991.54 %

NeOnc Technologies Holdings's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-35.28/( (2.824+3.33)/ 2 )
=-35.28/3.077
=-1,146.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -1,146.57% mean?
NeOnc Technologies Holdings (NTHI) has a ROA % of -1,146.57% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on NeOnc Technologies Holdings and its competitors. According to the industry distribution chart, NeOnc Technologies Holdings ranks #1404 out of 1417 companies in the Biotechnology industry, placing it in the top 99.1%.
Is NeOnc Technologies Holdings' ROA % too high?
NeOnc Technologies Holdings' current ROA % is -1,146.57%. Based on the distribution chart, NeOnc Technologies Holdings ranks #1404 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' ROA % compare to GUTS and PEPG?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #1404 out of 1417 companies for ROA %. This places NeOnc Technologies Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current ROA % is -1,146.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current ROA % of -1,146.57%. The current ROA % is -1,146.57%. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current ROA % is -1,146.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price